Adynxx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 6
- Market Cap
- -
- Website
- http://www.adynxx.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 2:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (100.0%)Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores
Phase 2
Withdrawn
- Conditions
- Pain, Postoperative
- Interventions
- Drug: Placebo 6 mL
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Adynxx, Inc.
- Registration Number
- NCT04104919
Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores
Phase 2
Withdrawn
- Conditions
- Pain, Postoperative
- Interventions
- Drug: Placebo 6 mL
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Adynxx, Inc.
- Registration Number
- NCT03797612
- Locations
- 🇺🇸
Research Site, Phoenix, Arizona, United States
Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
Phase 2
Completed
- Conditions
- Post-surgical Pain
- Interventions
- Drug: AYX1 Injection 660 mg/6 mLDrug: Placebo Injection 6 mL
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Adynxx, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT02807428
- Locations
- 🇺🇸
Alabama Orthopedic Center, Birmingham, Alabama, United States
🇺🇸Shoals Medical Trials, Sheffield, Alabama, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
Phase 2
Completed
- Conditions
- Postsurgical Pain
- Interventions
- Drug: AYX1 Injection 660 mg / 6 mLDrug: Placebo Injection 6 mLDrug: AYX1 Injection 1100 mg / 10 mLDrug: Placebo Injection 10 mL
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Adynxx, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02081703
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery
Phase 2
Completed
- Conditions
- Postsurgical Pain
- Interventions
- Drug: AYX1 Injection 330 mgDrug: Placebo InjectionDrug: AYX1 Injection 110 mg
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Adynxx, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01731730
News
No news found